Join BCG at the intersection of innovation and investment in health care—the annual J.P. Morgan Healthcare Conference, taking place Jan. 13-15 in San Francisco, where leading thinkers will convene to talk through the future of the industry.
BCG’s health care experts will be in San Francisco alongside the J.P. Morgan Healthcare Conference – the industry’s largest investment symposium – to engage with industry leaders, emerging fast-growth companies, innovative technology creators, and leaders in the investment community. Our contingent of thought leaders will share their insights across biopharma, medical devices and technology, payers and providers, and global health, and we will explore the latest developments in digital health and AI innovations such as novel therapies, and how M&A is reshaping the competitive landscape.
Learn more about BCG’s latest work with health care clients.
BCG and Zeiss developed an application to give prospective patients fast, accurate, validated answers about elective treatments.
LEARN MORE
How BCG used a cascaded and holistic organization-design approach to help a global biotech firm reduce its gross labor and non-labor costs by 20%.
LEARN MORE
BCG X partners to leverage new AI tools and platform to enhance clinical trials, speeding up medical innovations, life-changing therapies, and patient outcomes.
LEARN MORE
Our GenAI Collaboration with Merck
This year, BCG launched a collaboration with Merck aimed at advancing the discovery and assessment of novel drug targets for chronic and degenerative diseases through AI.
BCG’s second annual report reviews the growth of new drug modalities over the past year and addresses the potential impact on the biopharmaceutical industry.
New GenAI offerings can benefit virtually every aspect of an organization, boosting efficiency and productivity in areas ranging from R&D to commercial activities.
To realize the promise and potential for GenAI, medtech executives must make swift and targeted efforts.
Costs for genomic sequencing have dropped steeply, making new types of genetic tests more accessible and changing the business model for the labs that run them.
The rise of GenAI brings tremendous opportunity. But to cut through the hype and identify future winners, investors should focus on four innovation hot spots.
The global biopharma company’s chief data and technology officer discusses its initiative to inject digital capabilities across the value chain and the importance of prioritizing patient outcomes.
